SEFFILINE was founded in 2018 with the aim of making autologous regenerative therapy accessible to everyone.
For some years, autologous regenerative therapy using mesenchymal stem cells of adipose origin has been considered a state-of-art technology, and is supported by an enormous scientific literature.
In 2019 SEFFILINE started producing and selling the first and only medical device that enables autologous regenerative therapy using mesenchymal stem cells of adipose origin.
The device is all-in-one, disposable, standardized, safe, and inexpensive. It can be used in medical surgeries without the need for operating theatres and costly machinery, by doctors of any specialization and without specific skills for the collection of adipose tissue.
SEFFILINE has established exclusive distribution contracts with contracted minimum sales limits in the following countries: Italy, United Kingdom, Australia, New Zealand, United Arab Emirates and Saudi Arabia, Indonesia, Philippines and Thailand, and Brazil, with further contacts underway in Poland, Spain, Germany, France, Ukraine, Israel, Jordan, Mexico, Turkey, and Russia.
Currently most of the distributors are working to obtain product approvals in their respective countries and training their agents. SEFFILINE's Academy conducts selection and instruction for trainers, medical opinion leaders, and ‘ambassadors’ who instruct the final customer doctors.